RATIONALE: Beryllium sensitization (BeS) and chronic beryllium disease (CBD) are determined by at least one genetic factor, a glutamic acid at position 69 (E69) of the HLA-DPB1 gene, and by exposure to beryllium. The relationship between exposure and the E69 genotype has not been well characterized. OBJECTIVES: The study goal was to define the relationship between beryllium exposure and E69 for CBD and BeS. METHODS: Workers (n = 386) from a U.S. nuclear weapons facility were enrolled into a case-control study (70 BeS, 61 CBD, and 255 control subjects). HLA-DPB1 genotypes were determined by sequence-specific primer-polymerase chain reaction. Beryllium exposures were reconstructed on the basis of worker interviews and historical exposure measurements. MEASUREMENTS AND MAIN RESULTS: Any E69 carriage increased odds for CBD (odds ratio [OR], 7.61; 95% confidence interval [CI], 3.66-15.84) and each unit increase in lifetime weighted average exposure increased the odds for CBD (OR, 2.27; 95% CI, 1.26-4.09). Compared with E69-negative genotypes, a single E69-positive *02 allele increased the odds for BeS (OR, 12.01; 95% CI, 4.28-33.71) and CBD (OR, 3.46; 95% CI, 1.42-8.43). A single non-*02 E69 allele further increased the odds for BeS (OR, 29.54; 95% CI, 10.33-84.53) and CBD (OR, 11.97; 95% CI, 5.12-28.00) and two E69 allele copies conferred the highest odds for BeS (OR, 55.68; 95% CI, 14.80-209.40) and CBD (OR, 22.54; 95% CI, 7.00-72.62). CONCLUSIONS: E69 and beryllium exposure both contribute to the odds of CBD. The increased odds for CBD and BeS due to E69 appear to be differentially distributed by genotype, with non-*02 E69 carriers and E69 homozygotes at higher odds than those with *02 genotypes.
RATIONALE: Beryllium sensitization (BeS) and chronic beryllium disease (CBD) are determined by at least one genetic factor, a glutamic acid at position 69 (E69) of the HLA-DPB1 gene, and by exposure to beryllium. The relationship between exposure and the E69 genotype has not been well characterized. OBJECTIVES: The study goal was to define the relationship between beryllium exposure and E69 for CBD and BeS. METHODS: Workers (n = 386) from a U.S. nuclear weapons facility were enrolled into a case-control study (70 BeS, 61 CBD, and 255 control subjects). HLA-DPB1 genotypes were determined by sequence-specific primer-polymerase chain reaction. Beryllium exposures were reconstructed on the basis of worker interviews and historical exposure measurements. MEASUREMENTS AND MAIN RESULTS: Any E69 carriage increased odds for CBD (odds ratio [OR], 7.61; 95% confidence interval [CI], 3.66-15.84) and each unit increase in lifetime weighted average exposure increased the odds for CBD (OR, 2.27; 95% CI, 1.26-4.09). Compared with E69-negative genotypes, a single E69-positive *02 allele increased the odds for BeS (OR, 12.01; 95% CI, 4.28-33.71) and CBD (OR, 3.46; 95% CI, 1.42-8.43). A single non-*02 E69 allele further increased the odds for BeS (OR, 29.54; 95% CI, 10.33-84.53) and CBD (OR, 11.97; 95% CI, 5.12-28.00) and two E69 allele copies conferred the highest odds for BeS (OR, 55.68; 95% CI, 14.80-209.40) and CBD (OR, 22.54; 95% CI, 7.00-72.62). CONCLUSIONS: E69 and beryllium exposure both contribute to the odds of CBD. The increased odds for CBD and BeS due to E69 appear to be differentially distributed by genotype, with non-*02 E69 carriers and E69 homozygotes at higher odds than those with *02 genotypes.
Authors: Kenneth Rosenman; Vicki Hertzberg; Carol Rice; Mary Jo Reilly; Judith Aronchick; John E Parker; Jackie Regovich; Milton Rossman Journal: Environ Health Perspect Date: 2005-10 Impact factor: 9.031
Authors: Elizabeth Fireman; Yehuda Lerman; Moshe Stark; Asher Pardo; Yehuda Schwarz; Michael V Van Dyke; Jill Elliot; Briana Barkes; Lee Newman; Lisa Maier Journal: J Occup Environ Hyg Date: 2014 Impact factor: 2.155
Authors: Kathleen Kreiss; Ethan D Fechter-Leggett; Erin C McCanlies; Christine R Schuler; Ainsley Weston Journal: J Occup Environ Med Date: 2016-09 Impact factor: 2.162
Authors: Lori J Silveira; Erin C McCanlies; Tasha E Fingerlin; Michael V Van Dyke; Margaret M Mroz; Matthew Strand; Andrew P Fontenot; Natalie Bowerman; Dana M Dabelea; Christine R Schuler; Ainsley Weston; Lisa A Maier Journal: J Immunol Date: 2012-09-12 Impact factor: 5.422
Authors: James Crooks; Margaret M Mroz; Michael VanDyke; Alison McGrath; Christine Schuler; Erin C McCanlies; M Abbas Virji; Kenneth D Rosenman; Milton Rossman; Carol Rice; Dimitri Monos; Tasha E Fingerlin; Lisa A Maier Journal: Occup Environ Med Date: 2021-09-17 Impact factor: 4.402
Authors: M T Falta; A N Tinega; D G Mack; N A Bowerman; F Crawford; J W Kappler; C Pinilla; A P Fontenot Journal: Mucosal Immunol Date: 2015-07-01 Impact factor: 7.313
Authors: Marharyta Petukh; Bohua Wu; Shannon Stefl; Nick Smith; David Hyde-Volpe; Li Wang; Emil Alexov Journal: PLoS One Date: 2014-11-04 Impact factor: 3.240
Authors: Lori J Silveira; Matthew Strand; Michael V Van Dyke; Margaret M Mroz; Anna V Faino; Dana M Dabelea; Lisa A Maier; Tasha E Fingerlin Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240